ClinVar Miner

Submissions for variant NM_004360.5(CDH1):c.650C>T (p.Thr217Ile)

dbSNP: rs778382252
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000216872 SCV000275983 uncertain significance Hereditary cancer-predisposing syndrome 2022-03-23 criteria provided, single submitter clinical testing The p.T217I variant (also known as c.650C>T), located in coding exon 5 of the CDH1 gene, results from a C to T substitution at nucleotide position 650. The threonine at codon 217 is replaced by isoleucine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Labcorp Genetics (formerly Invitae), Labcorp RCV001323284 SCV001514192 uncertain significance Hereditary diffuse gastric adenocarcinoma 2020-08-26 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with CDH1-related conditions. ClinVar contains an entry for this variant (Variation ID: 231975). This variant is not present in population databases (ExAC no frequency). This sequence change replaces threonine with isoleucine at codon 217 of the CDH1 protein (p.Thr217Ile). The threonine residue is highly conserved and there is a moderate physicochemical difference between threonine and isoleucine.
Baylor Genetics RCV004567585 SCV005060096 uncertain significance Familial cancer of breast 2024-01-20 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.